Literature DB >> 26475495

Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Ansgar Heck1,2, Kyrre E Emblem3, Olivera Casar-Borota4,5, Jens Bollerslev6,7, Geir Ringstad8.   

Abstract

In growth hormone (GH)-producing adenomas, T2-weighted MRI signal intensity is a marker for granulation pattern and response to somatostatin analogs (SSA). Prediction of treatment response is necessary for individualized treatment, and T2 intensity assessment might improve preoperative classification of somatotropinomas. The objectives of this study are (I) to explore the feasibility of quantitative T2-weighted MRI histogram analyses in newly diagnosed somatotroph adenomas and their relation to clinical and histological parameters and (II) to compare the quantitative method to conventional, visual assessment of T2 intensity. The study was a retrospective cohort study of 58 newly diagnosed patients. In 34 of these, response to primary SSA treatment after median 6 months was evaluated. Parameters from the T2 histogram analyses (T2 intensity ratio and T2 homogeneity ratio) were correlated to visually assessed T2 intensity (hypo-, iso-, hyperintense), baseline characteristics, response to SSA treatment, and histological granulation pattern (anti-Cam5.2). T2 intensity ratio was lowest in the hypointense tumors and highest in the hyperintense tumors (0.66 ± 0.10 vs. 1.07 ± 0.11; p < 0.001). T2 intensity at baseline correlated with reduction in GH (r = -0.67; p < 0.001) and IGF-1 (r = -0.36; p = 0.037) after primary SSA treatment (n = 34). The T2 homogeneity ratio correlated with adenoma size reduction (r = -0.45; p = 0.008). Sparsely granulated adenomas had a higher T2 intensity than densely or intermediately granulated adenomas. T2 histogram analyses are an applicable tool to assess T2 intensity in somatotroph adenomas. Quantitatively assessed T2 intensity ratio in GH-producing adenomas correlates with conventional assessment of T2 intensity, baseline characteristics, response to SSA treatment, and histological granulation pattern.

Entities:  

Keywords:  Acromegaly; Granulation; MRI; Somatostatin analog; T2

Mesh:

Substances:

Year:  2015        PMID: 26475495     DOI: 10.1007/s12020-015-0766-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Geir Ringstad; Stine L Fougner; Olivera Casar-Borota; Terje Nome; Jon Ramm-Pettersen; Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

2.  Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Authors:  Ming Shen; Xuefei Shou; Yongfei Wang; Zhaoyun Zhang; Jinsong Wu; Ying Mao; Shiqi Li; Yao Zhao
Journal:  Endocr J       Date:  2010-11-16       Impact factor: 2.349

3.  Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.

Authors:  S L Fougner; J Bollerslev; J Svartberg; M Øksnes; J Cooper; S M Carlsen
Journal:  Eur J Endocrinol       Date:  2014-05-27       Impact factor: 6.664

4.  Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.

Authors:  Iulia Potorac; Patrick Petrossians; Adrian F Daly; Franck Schillo; Claude Ben Slama; Sonia Nagi; Mouna Sahnoun; Thierry Brue; Nadine Girard; Philippe Chanson; Ghaidaa Nasser; Philippe Caron; Fabrice Bonneville; Gérald Raverot; Véronique Lapras; François Cotton; Brigitte Delemer; Brigitte Higel; Anne Boulin; Stéphan Gaillard; Florina Luca; Bernard Goichot; Jean-Louis Dietemann; Albert Beckers; Jean-François Bonneville
Journal:  Endocr Relat Cancer       Date:  2015-01-02       Impact factor: 5.678

5.  The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment.

Authors:  Nicoleta C Olarescu; Ansgar Heck; Kristin Godang; Thor Ueland; Jens Bollerslev
Journal:  Neuroendocrinology       Date:  2015-01-09       Impact factor: 4.914

6.  Volume of pituitary macroadenomas: assessment by MRI.

Authors:  P Lundin; F Pedersen
Journal:  J Comput Assist Tomogr       Date:  1992 Jul-Aug       Impact factor: 1.826

7.  Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.

Authors:  Lei Zhang; Xiaojun Wu; Yong Yan; Jun Qian; Yicheng Lu; Chun Luo
Journal:  Brain Dev       Date:  2014-05-10       Impact factor: 1.961

8.  Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Authors:  Abdulkader Obari; Toshiaki Sano; Kenichi Ohyama; Eiji Kudo; Zhi Rong Qian; Akiko Yoneda; Nasim Rayhan; Muhammad Mustafizur Rahman; Shozo Yamada
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps.

Authors:  Kyrre E Emblem; Baard Nedregaard; Terje Nome; Paulina Due-Tonnessen; John K Hald; David Scheie; Olivera Casar Borota; Milada Cvancarova; Atle Bjornerud
Journal:  Radiology       Date:  2008-06       Impact factor: 11.105

Review 10.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  28 in total

1.  MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2015-11-28       Impact factor: 3.633

2.  Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.

Authors:  Burak Kocak; Emine Sebnem Durmaz; Pinar Kadioglu; Ozge Polat Korkmaz; Nil Comunoglu; Necmettin Tanriover; Naci Kocer; Civan Islak; Osman Kizilkilic
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

3.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 4.  T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.

Authors:  Iulia Potorac; Albert Beckers; Jean-François Bonneville
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

6.  Tumor T2 signal intensity and stalk angulation correlates with endocrine status in pituitary adenoma patients: a quantitative 7 tesla MRI study.

Authors:  John W Rutland; Puneet Pawha; Puneet Belani; Bradley N Delman; Corey M Gill; Teresa Brown; Khadeen Cheesman; Raj K Shrivastava; Priti Balchandani
Journal:  Neuroradiology       Date:  2020-01-10       Impact factor: 2.804

7.  T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.

Authors:  M C Burlacu; D Maiter; T Duprez; E Delgrange
Journal:  Endocrine       Date:  2018-09-28       Impact factor: 3.633

8.  Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ming Shen; Qilin Zhang; Wenjuan Liu; Meng Wang; Jingjing Zhu; Zengyi Ma; Wenqiang He; Shiqi Li; Xuefei Shou; Yiming Li; Zhaoyun Zhang; Hongying Ye; Min He; Bin Lu; Zhenwei Yao; Yun Lu; Nidan Qiao; Zhao Ye; Yichao Zhang; Yeping Yang; Yao Zhao; Yongfei Wang
Journal:  Neuroradiology       Date:  2016-08-11       Impact factor: 2.804

9.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

10.  Prediction of high proliferative index in pituitary macroadenomas using MRI-based radiomics and machine learning.

Authors:  Lorenzo Ugga; Renato Cuocolo; Domenico Solari; Elia Guadagno; Alessandra D'Amico; Teresa Somma; Paolo Cappabianca; Maria Laura Del Basso de Caro; Luigi Maria Cavallo; Arturo Brunetti
Journal:  Neuroradiology       Date:  2019-08-02       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.